S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
[BREAKING] Pentagon to Spend Billions on "Living Missile" (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
Chuck Todd leaving NBC political panel show 'Meet the Press' and being replaced by Kristen Welker

TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News

$0.62
+0.05 (+8.80%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.57
$0.62
50-Day Range
$0.57
$2.06
52-Week Range
$0.55
$2.32
Volume
100,217 shs
Average Volume
81,944 shs
Market Capitalization
$15.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,086.6% Upside
$7.33 Price Target
Short Interest
Healthy
0.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$243,460 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.56) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

256th out of 983 stocks

Biological Products, Except Diagnostic Industry

34th out of 164 stocks


TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
TRACON Pharmaceuticals (NASDAQ:TCON) PT Lowered to $3.00
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Recap: TRACON Pharma Q1 Earnings
Q1 2023 TRACON Pharmaceuticals Inc Earnings Call
BTIG Reaffirms Their Buy Rating on TRACON Pharmaceuticals (TCON)
Maxim Group Keeps Their Buy Rating on TRACON Pharmaceuticals (TCON)
See More Headlines

TCON Price History

TCON Company Calendar

Last Earnings
3/08/2023
Today
6/04/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,086.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-29,140,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
($0.46) per share

Miscellaneous

Free Float
22,791,000
Market Cap
$15.29 million
Optionable
Not Optionable
Beta
1.36

Key Executives

  • Charles P. TheuerCharles P. Theuer
    President, Chief Executive Officer & Director
  • Bonne J. Adams
    Chief Operating Officer & Executive VP
  • Scott B. Brown
    Chief Financial Officer
  • James L. Freddo
    Chief Medical Officer
  • Brenda Marczi
    Senior Vice President-Regulatory Affairs













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares.
View TCON analyst ratings
or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2023?

1 Wall Street analysts have issued 1-year target prices for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 1,086.6% from the stock's current price.
View analysts price targets for TCON
or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2023?

TRACON Pharmaceuticals' stock was trading at $1.49 at the beginning of the year. Since then, TCON stock has decreased by 58.5% and is now trading at $0.6180.
View the best growth stocks for 2023 here
.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 161,000 shares, a decrease of 38.7% from the April 30th total of 262,500 shares. Based on an average daily trading volume, of 181,900 shares, the days-to-cover ratio is currently 0.9 days.
View TRACON Pharmaceuticals' Short Interest
.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our TCON earnings forecast
.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings data on Wednesday, March, 8th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.71%), Susquehanna International Group LLP (0.17%), Charles Schwab Investment Management Inc. (0.10%), Jane Street Group LLC (0.07%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends
.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $0.62.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $15.29 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-29,140,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -